Detalles de la búsqueda
1.
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Hepatology
; 78(5): 1558-1568, 2023 11 01.
Artículo
Inglés
| MEDLINE | ID: mdl-37184202
2.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Artículo
Inglés
| MEDLINE | ID: mdl-37789669
3.
Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.
Hepatol Res
; 2024 Apr 29.
Artículo
Inglés
| MEDLINE | ID: mdl-38685853
4.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Artículo
Inglés
| MEDLINE | ID: mdl-37983642
5.
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Cancer
; 129(4): 590-599, 2023 02 15.
Artículo
Inglés
| MEDLINE | ID: mdl-36426410
6.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Artículo
Inglés
| MEDLINE | ID: mdl-36455517
7.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Artículo
Inglés
| MEDLINE | ID: mdl-37307798
8.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Artículo
Inglés
| MEDLINE | ID: mdl-37552968
9.
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
BMC Gastroenterol
; 23(1): 101, 2023 Mar 31.
Artículo
Inglés
| MEDLINE | ID: mdl-37003980
10.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res
; 53(8): 737-748, 2023 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-37020416
11.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Artículo
Inglés
| MEDLINE | ID: mdl-37306040
12.
Apolipoprotein A2 isoforms associated with exocrine pancreatic insufficiency in early chronic pancreatitis.
J Gastroenterol Hepatol
; 38(11): 1949-1957, 2023 Nov.
Artículo
Inglés
| MEDLINE | ID: mdl-37501507
13.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol
; 38(8): 1389-1397, 2023 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-37231943
14.
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology
; 100(12): 645-654, 2022.
Artículo
Inglés
| MEDLINE | ID: mdl-36103846
15.
Prophylactic clip closure for mucosal defects is associated with reduced adverse events after colorectal endoscopic submucosal dissection: a propensity-score matching analysis.
BMC Gastroenterol
; 22(1): 139, 2022 Mar 26.
Artículo
Inglés
| MEDLINE | ID: mdl-35346047
16.
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
Hepatol Res
; 52(5): 462-470, 2022 May.
Artículo
Inglés
| MEDLINE | ID: mdl-35080087
17.
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hepatol Res
; 52(3): 308-316, 2022 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-34799975
18.
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
Hepatol Res
; 52(9): 773-783, 2022 Sep.
Artículo
Inglés
| MEDLINE | ID: mdl-35633504
19.
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Oncology
; 99(8): 518-527, 2021.
Artículo
Inglés
| MEDLINE | ID: mdl-33906189
20.
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
Liver Int
; 41(12): 2997-3008, 2021 12.
Artículo
Inglés
| MEDLINE | ID: mdl-34250737